• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi Winthrop Industrie

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
July 22, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi completes acquisition of Blueprint Medicines
July 18, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi announces extension of Blueprint tender offer
July 17, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
July 16, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press release: Availability of the Q2 2025 Aide mémoire
June 30, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
June 30, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
June 25, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
June 23, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
June 20, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press release: Sanofi successfully prices €1.5 billion bond issue
June 17, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
June 15, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
June 09, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
June 05, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
June 03, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
June 03, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
June 02, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
May 30, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
May 29, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi completes acquisition of DR-0201
May 27, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
May 21, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Annual General Meeting of April 30, 2025
April 30, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
April 30, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
April 29, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
April 24, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
April 18, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
April 15, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
April 08, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
April 03, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
March 28, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
March 28, 2025
From Sanofi Winthrop Industrie
Via GlobeNewswire
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap